Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females

Last updated: April 15, 2025
Sponsor: Ankara Yildirim Beyazıt University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Polymyositis (Inflammatory Muscle Disease)

Sarcopenia

Pain (Pediatric)

Treatment

Placebo (Maltodextrin)

Creatine Monohydrate

Clinical Study ID

NCT06937190
162593019
  • Ages 18-25
  • Female
  • Accepts Healthy Volunteers

Study Summary

This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Female, aged 18 to 25 years

Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)

Regular menstrual cycles (used for scheduling purposes)

Able and willing to provide informed consent

Agreement to maintain normal diet and training routines throughout the study

Exclusion

Exclusion Criteria:

History of musculoskeletal injury affecting lower or upper limbs within the past 6 months

Known allergy or intolerance to creatine or maltodextrin

Use of performance-enhancing substances or supplements within the last 30 days

Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period

Current use of anti-inflammatory medication

Pregnancy or breastfeeding

Inability to comply with study protocol or scheduled assessments

Study Design

Total Participants: 24
Treatment Group(s): 2
Primary Treatment: Placebo (Maltodextrin)
Phase:
Study Start date:
April 01, 2025
Estimated Completion Date:
July 10, 2025

Connect with a study center

  • Islamic Azad University, Shabestar Branch

    Shabestar, East Azerbaijan 5381637183
    Iran, Islamic Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.